1. Home
  2. VHC vs BMEA Comparison

VHC vs BMEA Comparison

Compare VHC & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VirnetX Holding Corp

VHC

VirnetX Holding Corp

HOLD

Current Price

$14.05

Market Cap

79.2M

Sector

Miscellaneous

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.32

Market Cap

90.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VHC
BMEA
Founded
2005
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.2M
90.5M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
VHC
BMEA
Price
$14.05
$1.32
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$8.71
AVG Volume (30 Days)
8.9K
1.1M
Earning Date
03-24-2026
03-24-2026
Dividend Yield
N/A
N/A
EPS Growth
0.99
69.19
EPS
N/A
N/A
Revenue
$162,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3140.00
N/A
52 Week Low
$6.60
$0.87
52 Week High
$29.00
$3.07

Technical Indicators

Market Signals
Indicator
VHC
BMEA
Relative Strength Index (RSI) 41.41 51.19
Support Level $12.88 $1.22
Resistance Level $18.36 $1.47
Average True Range (ATR) 1.41 0.11
MACD 0.03 0.00
Stochastic Oscillator 16.95 50.56

Price Performance

Historical Comparison
VHC
BMEA

About VHC VirnetX Holding Corp

VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: